- Home
- MRCC vs APLT Comparison
MRCC vs APLT Comparison
Compare MRCC & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- APLT
- Stock Information
- Founded
- MRCC 2011
- APLT 2016
- Country
- MRCC United States
- APLT United States
- Employees
- MRCC N/A
- APLT N/A
- Industry
- MRCC Investment Managers
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- APLT Health Care
- Exchange
- MRCC Nasdaq
- APLT Nasdaq
- Market Cap
- MRCC 151.7M
- APLT 178.6M
- IPO Year
- MRCC 2012
- APLT 2019
- Fundamental
- Price
- MRCC $7.00
- APLT $1.05
- Analyst Decision
- MRCC Hold
- APLT Buy
- Analyst Count
- MRCC 1
- APLT 5
- Target Price
- MRCC $8.00
- APLT $4.13
- AVG Volume (30 Days)
- MRCC 98.5K
- APLT 11.7M
- Earning Date
- MRCC 11-11-2025
- APLT 11-06-2025
- Dividend Yield
- MRCC 14.24%
- APLT N/A
- EPS Growth
- MRCC N/A
- APLT N/A
- EPS
- MRCC 0.09
- APLT N/A
- Revenue
- MRCC $51,229,000.00
- APLT $121,000.00
- Revenue This Year
- MRCC N/A
- APLT N/A
- Revenue Next Year
- MRCC N/A
- APLT $5,931.24
- P/E Ratio
- MRCC $79.46
- APLT N/A
- Revenue Growth
- MRCC N/A
- APLT N/A
- 52 Week Low
- MRCC $5.96
- APLT $0.30
- 52 Week High
- MRCC $8.85
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MRCC 40.33
- APLT 65.38
- Support Level
- MRCC $6.90
- APLT $0.56
- Resistance Level
- MRCC $7.13
- APLT $1.32
- Average True Range (ATR)
- MRCC 0.17
- APLT 0.17
- MACD
- MRCC -0.05
- APLT 0.05
- Stochastic Oscillator
- MRCC 12.64
- APLT 69.68
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.